Shares of Profound Medicl (NYSE:PROF) have been assigned an average rating of “Buy” from the six brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $25.33.
Several analysts have commented on the stock. Raymond James raised their target price on shares of Profound Medicl from $38.00 to $43.00 and gave the stock a “strong-buy” rating in a report on Friday, July 31st. Zacks Investment Research downgraded shares of Profound Medicl from a “hold” rating to a “sell” rating in a report on Tuesday, July 14th. Finally, Alliance Global Partners restated a “buy” rating and set a $18.00 target price (up from $15.00) on shares of Profound Medicl in a report on Friday, August 7th.
NYSE:PROF traded up $0.61 during mid-day trading on Tuesday, reaching $14.84. 63,957 shares of the company were exchanged, compared to its average volume of 75,714. The company has a fifty day moving average of $15.42 and a 200 day moving average of $13.57. Profound Medicl has a 12 month low of $6.24 and a 12 month high of $20.60.
Hedge funds have recently made changes to their positions in the business. UBS Group AG grew its stake in shares of Profound Medicl by 406.4% during the 1st quarter. UBS Group AG now owns 3,545 shares of the company’s stock worth $34,000 after acquiring an additional 2,845 shares in the last quarter. Bessemer Group Inc. bought a new position in shares of Profound Medicl during the 2nd quarter worth approximately $54,000. Bank of America Corp DE bought a new position in shares of Profound Medicl during the 4th quarter worth approximately $57,000. Raymond James & Associates bought a new position in shares of Profound Medicl during the 1st quarter worth approximately $100,000. Finally, CIBC World Markets Inc. bought a new position in shares of Profound Medicl during the 1st quarter worth approximately $127,000.
About Profound Medicl
Profound Medical Corp. operates as a medical technology company focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. It is developing a treatment to ablate the prostate gland in prostate cancer patients, treatment of uterine fibroids and nerves, and palliative pain treatment for patients with metastatic bone disease.
Featured Story: What is a front-end load?
Receive News & Ratings for Profound Medicl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medicl and related companies with MarketBeat.com's FREE daily email newsletter.